Ionis Pharmaceuticals Inc IONS

NAS: IONS | ISIN: US4622221004   30/04/2025
30,71 USD (+3,02%)
(+3,02%)   30/04/2025

10 september 2024 · Ionis announces pricing of $500.3 million public offering · Persbericht

9 september 2024 · Ionis announces proposed public offering of common stock · Persbericht

28 augustus 2024 · Ionis to present at upcoming investor conferences · Persbericht

1 augustus 2024 · Ionis reports second quarter 2024 financial results · Persbericht

31 juli 2024 · Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen · Persbericht

22 juli 2024 · Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome · Persbericht

19 juli 2024 · Ionis to hold second quarter 2024 financial results webcast · Persbericht

18 juli 2024 · Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease · Persbericht

8 juli 2024 · Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome · Persbericht

25 juni 2024 · Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed · Persbericht

18 juni 2024 · Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema · Persbericht

17 juni 2024 · Ionis to present at TD Cowen Genetic Medicines & RNA Summit · Persbericht

31 mei 2024 · Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema · Persbericht

28 mei 2024 · Ionis to hold donidalorsen Phase 3 data webcast · Persbericht

23 mei 2024 · New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) · Persbericht

16 mei 2024 · Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis · Persbericht

16 mei 2024 · Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome · Persbericht

15 mei 2024 · Ionis to host 2024 virtual Annual Meeting of Stockholders · Persbericht

7 mei 2024 · Ionis reports first quarter 2024 financial results · Persbericht

25 april 2024 · Ionis Publishes 2023 Corporate Responsibility Report · Persbericht

Mijn selecties